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ARTICLE
Release of Staphylococcus aureus extracellular
vesicles and their application as a vaccine platform
Xiaogang Wang1, Christopher D. Thompson1, Christopher Weidenmaier 2,3 & Jean C. Lee1
Secretion of extracellular vesicles (EVs), a process common to eukaryotes, archae, and
bacteria, represents a secretory pathway that allows cell-free intercellular communication.
Microbial EVs package diverse proteins and inﬂuence the host-pathogen interaction, but the
mechanisms underlying EV production in Gram-positive bacteria are poorly understood. Here
we show that EVs puriﬁed from community-associated methicillin-resistant Staphylococcus
aureus package cytosolic, surface, and secreted proteins, including cytolysins. Staphylococcal
alpha-type phenol-soluble modulins promote EV biogenesis by disrupting the cytoplasmic
membrane; whereas, peptidoglycan cross-linking and autolysin activity modulate EV
production by altering the permeability of the cell wall. We demonstrate that EVs puriﬁed
from a S. aureus mutant that is genetically engineered to express detoxiﬁed cytolysins are
immunogenic in mice, elicit cytolysin-neutralizing antibodies, and protect the animals in a
lethal sepsis model. Our study reveals mechanisms underlying S. aureus EV production and
highlights the usefulness of EVs as a S. aureus vaccine platform.
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Staphylococcus aureus is a pathogenic bacterium that causes awide spectrum of human infections, ranging from mild skinlesions to invasive, life-threatening infections. The
pathogenesis of S. aureus infections is attributed to a wide array of
virulence determinants, including surface proteins1 and
glycopolymers2, as well as multiple secreted proteins, such as
superantigens, leukotoxins, hemolysins, and proteases3. Although
several speciﬁc export pathways have been described in S. aureus,
the secretome often includes proteins that lack export signals and
have typical cytoplasmic functions. The mechanisms by which
cytoplasmic proteins are excreted by S. aureus have attracted
recent interest4,5, and there is increasing evidence that these
proteins may be secreted within extracellular membrane vesicles
(EVs)6–9.
EVs are nano-sized, spherical, bilayered membrane vesicles
with a cargo that includes diverse proteins, polysaccharides,
nucleic acids, and lipids. EV formation by Gram-negative bacteria
was ﬁrst observed by electron microscopy in the 1960s10, and
these bacteria secrete what are now referred to as outer
membrane vesicles (OMVs). The generation of OMVs occurs by
phospholipid accumulation in the outer leaﬂet of the outer
membrane, followed by the formation of outer membrane pro-
trusions that pinch off to form vesicles11. OMVs likely play
important roles in bacterial pathogenesis due to packaging of
multiple virulence factors12, and the ability of OMVs to serve as
immune modulators by inducing innate and adaptive immune
responses13.
Recent work has described the production and release of EVs
from Gram-positive bacteria and fungi6–9,14. Because of the thick
peptidoglycan (PGN) structure typical of Gram-positive
microbes, EV biogenesis is a complex and poorly understood
process. Toyofuku et al.14 recently reported that membrane
vesicle formation in Bacillus subtilis was a result of prophage-
encoded endolysins that generated holes in the PGN, facilitating
EV release. EVs from Gram-positive organisms play important
roles in host-pathogen interactions, as supported by reports that
EVs contain biologically active toxins, exhibit cytotoxicity, and
elicit proinﬂammatory mediators9. Moreover, toxin-positive
S. aureus EVs elicit skin barrier disruption in mice with
characteristic atopic dermatitis-like skin inﬂammation15,16. The
toxicity of staphylococcal EVs has hampered a relevant study of
their immunogenicity and potential use as a vaccine platform.
Despite repeated efforts to develop experimental vaccines and
immunotherapeutics against S. aureus, neither have proven
effective in preventing staphylococcal infections in humans17.
Mice immunized with native S. aureus EVs produced a robust
T-cell response and were protected against lung infection, but EV
toxicity was not addressed in this study18. The development of
EVs as a S. aureus vaccine platforms will require characterization
of the mechanisms of EV biogenesis to enable consistent
production with adequate quality assurance.
In this study, we generate EVs from a predominant
community-acquired, methicillin-resistant S. aureus (CA-MRSA)
clone in the United States. Our study reveals distinct mechanisms
that facilitate EV production at multiple stages. Phenol-soluble
modulins (PSMs) act at the membrane level to facilitate vesicle
budding at the cytoplasmic membrane; whereas, cell wall porosity
is modulated by PGN cross-linking and production of autolysins.
Our results demonstrate the cytotoxicity of native S. aureus EVs
for multiple cell types. By genetically engineering a non-toxic
S. aureus mutant to over-produce detoxiﬁed cytolysins, we show
that engineered EVs (eng-EVs) are immunogenic, non-toxic, and
1 2 3 4 5 6 7 8 9 10 11 KD
115
82
64
49
37
26
19
9–11
3–8
a b
c d
Fig. 1 Extracellular vesicles from S aureus JE2. The bacteria were cultivated in TSB. a Ultrathin sections of S. aureus JE2 examined by TEM revealed EVs
(indicated by a red arrow) released from the cell wall. b Crude EVs (red arrows) pelleted by ultracentrigation from the JE2 culture supernatant were imaged
by TEM. c EVs were puriﬁed by density gradient ultracentrifugation (Optiprep), and fractions were visualized by silver-stained SDS-PAGE. d Fractions 3–8
were pooled; OptiPrep was removed by diaﬁltration, and the samples were imaged by TEM. EVs were not visualized in fractions 9–11. Scale bar, 100 nm
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protect mice against S. aureus lethal sepsis. Our investigation
describes a vaccine platform and provides the basis for further
studies on the impact of EVs on the pathogenicity of S. aureus
and other Gram-positive pathogens.
Results
Isolation of S. aureus EVs. Ultrathin sections of JE219 cells
examined by transmission electron microscopy (TEM) revealed
vesicle-like structures released from the S. aureus cell surface
(Fig. 1a). We isolated the EVs by concentrating the culture
supernatants to remove molecules <100 kDa before
ultracentrifugation to pellet the EVs, shown in Fig. 1b. To remove
non-membranous proteins, protein aggregates, and denatured
EVs, Optiprep-based density gradient centrifugation was
performed on the crude EV preparations. Consecutive Optiprep
fractions (10 µl) were subjected to SDS-PAGE. Little silver-
stained material was recovered from fractions 1 and 2 (Fig. 1c).
Samples with similar protein banding patterns (fractions 3–8 and
9–11) were pooled, diaﬁltered, and examined by TEM. EVs were
observed in fractions 3–8 (Fig. 1d), but not from fractions 9–11,
indicating that EVs were distributed in fractions containing 20
−35% Optiprep.
Protein composition of S. aureus EVs. A proteomic analysis of
puriﬁed JE2 EVs by liquid chromatography–tandem mass
spectrometry (LC–MS/MS) identiﬁed 165 proteins (Supplementary
Data 1), including alpha toxin (Hla), leukocidin subunits (LukS-PV,
LukF-PV, LukE, LukD, HlgB, and HlgC), adhesins (ClfA, ClfB,
SdrD, SdrE, Efb, and Ebh), MntC, proteases, and immune evasion
factors (Sbi, phenol-soluble modulins, catalase, CHIPS, and SodA).
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Fig. 2 Alpha-type phenol-soluble modulin peptides promote S. aureus EV production. a EV production from strain LAC and its isogenic mutants lacking
psmα or psmβ was evaluated by dot-blotting EV suspensions puriﬁed from the same volume of bacterial culture, b by quantiﬁcation of total EV protein
abundance, or c by direct EV quantiﬁcation of EV particles with nanoparticle tracking analysis. d The size distribution and e average size of EVs puriﬁed
from WT and Δpsmα and Δpsmβ mutants were analyzed by dynamic light scattering, and the data were generated with ZataPALS particle sizing software.
Dot-blotting was repeated at least twice, and a representitative result is presented. Signal intensity quantiﬁed by Image Studio Lite software is shown above
the blot. EV quantiﬁcation by other methods was calculated from at least three independent experiments and expressed as mean ± s.e.m. f An electron
micrograph of WT strain JE2 carrying pTXΔ expressing the genes encoding PSMα1-4 is shown. Scale bar, 200 nm. Samples were compared with a One-
way ANOVA with Dunnett’s multiple comparison test (Fig. 2b, c) or with Tukey’s multiple comparison test (Fig. 2e). *P < 0.05, **P < 0.01, ***P < 0.001,
****P < 0.0001
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Other proteins of interest included penicillin-binding proteins,
autolysins (Atl, Sle1, and other putative autolysins with pre-
dicted N-acetylmuramoyl-L-alanine amidase activity), proteins
involved in iron acquisition, and multiple other lipoproteins.
Bioinformatic analyses revealed that 46% of EV proteins were
cytoplasmic (n= 76), 16% were extracellular proteins (n= 27), 16%
had an unknown localization (n= 27), 12% were membrane pro-
teins (n= 19), and 10% were cell wall associated proteins (n= 16).
Phenol-soluble modulins promote EV release. S. aureus secretes
PSMs, which are a family of amphipathic, alpha-helical,
surfactant-like peptides that are proinﬂammatory and show
cytolytic activity against neutrophils, erythrocytes, epithelial cells,
and endothelial cells20,21. Alpha-type PSMs are required for
mobilizing lipoproteins from the staphylococcal cytoplasmic
membrane, a process essential for activating TLR222, as well as
the export of cytoplasmic proteins, consistent with the
membrane-damaging activity of PSMs5. Because the cargo of
S. aureus EVs is enriched for both lipoproteins and cytoplasmic
proteins, we evaluated whether PSM peptides were critical for EV
generation.
We measured EV production by the WT USA300 LAC strain
(the parent strain of JE2), as well as LAC Δpsmα, Δpsmβ, and
ΔpsmαΔpsmβ mutants21. Dot immunoblot analysis revealed that
deletion of psmα genes reduced EV production (Fig. 2a).
Likewise, protein assays and nanoparticle tracking analysis
(NTA) indicated that the psmα mutant showed signiﬁcantly
reduced S. aureus EV yield (Fig. 2b) and particle number (Fig. 2c),
respectively. The Δpsmα and ΔpsmαΔpsmβ double mutant
produced comparable levels of EVs (Fig. 2b), indicating that
PSMα peptides play the dominant role in this phenotype.
Complemention with pTXΔ expressing PSMα1-4 genes, but not
the pTXΔ vector alone, restored EV production to the Δpsmα
mutant (Fig. 2b, c). Mutation of the psmα genes signiﬁcantly
reduced S. aureus EV size (Fig. 2c, d); whereas, the Δpsmβ mutant
produced EVs of intermediate size compared to that of wild-type
(WT) LAC. We transduced pTXΔPSMα1-421 into strain JE2, and
its EV yield (protein content) increased from 184 ± 12 to 650 ±
17 ng ml−1 (n= 3). Nonetheless, electron micrographs of JE2
(pTXΔPSMα1-4) showed intact bacterial cells producing abun-
dant EVs (Fig. 2f). Signiﬁcant differences in bacterial numbers
recovered from JE2 cultures with or without pTXΔPSMα1-4 were
not observed (Supplementary Fig. 1a), indicating minimal impact
of EV formation on bacterial viability.
PGN cross-linking modulates EVs production. Unlike OMVs
produced by Gram-negative microbes, S. aureus cytoplasmic
membrane-derived EVs must traverse a PGN cell wall structure
before cellular release. To determine whether the degree of PGN
cross-linking affected S. aureus EV biogenesis, we cultured S. aureus
JE2 in medium with a sublethal concentration (0.2 µgml−1) of
penicillin G (PenG) that has been shown to decrease PGN cross-
linking23. Treatment with a sublethal concentration (0.1 µgml−1) of
erythromycin (Em) served as an antibiotic control that has no effect
on PGN cross-linking. Compared to EVs recovered from untreated
cultures or cultures incubated with Em, the EV yield from
PenG-treated cultures was distinctly higher (Fig. 3a). When the EV
protein content was quantiﬁed from a ﬁxed volume of culture left
untreated or treated with sublethal antibiotic concentrations, we
observed a 10-fold increase in EV yield from PenG-treated cultures
(Fig. 3b). EV production had little effect on bacterial viability since
differences were not observed in bacterial numbers recovered from
JE2 cultured with or without PenG (Supplementary Fig. 1b).
S. aureus penicillin-binding protein 4 (PBP4) is a carbox-
ypeptidase that is essential for secondary cross-linking of PGN,
and a pbp4 mutant shows a signiﬁcant reduction in PGN cross-
linking24. As predicted, both dot blot (Fig. 3c) and EV protein
yield assays (Fig. 3d) showed increased EV production by
JE2Δpbp4, and the protein yield was threefold higher than the
wild-type JE2 strain. We also measured EV production in MRSA
isolates MW2, COL, and their Δpbp4 mutants; the relative
increase in EV yield in the mutant strains (Fig. 3c, d) was
consistent with that of JE2Δpbp4.
WTA is a PGN-anchored glycopolymer that is major
component of the S. aureus cell wall and plays a critical role in
cell wall homeostasis2. The tagO gene encodes an N-acetyl
glucosamine-phosphate transferase enzyme that catalyzes the ﬁrst
step in WTA biosynthesis25,26, and deletion of tagO gene
abrogates S. aureus WTA production27. Compared to the WT
strains JE2, COL, and Newman, tagO mutants showed an
enhanced signal in the dot immunoblot assay for EV production
(Fig. 3e). Likewise, quantitative analysis of EV protein yield
showed that all three tagO mutants produced signiﬁcantly more
EVs than the parental isolates (Fig. 3f). Thus, WTAs negatively
modulate S. aureus EV production, consistent with reports
showing that tagO mutants are characterized by diminished PGN
cross-linking28. The WTA backbone is decorated with ester-
linked D-ala residues, which confer a zwitterionic charge to the
polymer29. As shown in panels e and f of Fig. 3, production and
yield of EVs by the ΔdltA mutant were similar to that of the
parental strain Newman.
To determine whether EV size was affected by reduced PGN
cross-linking, the size distribution of puriﬁed EVs was measured
by dynamic light scattering (DSL). Treatment of JE2 cultures with
PenG or mutation of pbp4 or tagO resulted in a signiﬁcant
increase in the size distribution of EVs (Fig. 3g), as well as an
increased EV average size (Fig. 3h) compared to untreated WT
EVs. Because enhanced EV production and yield associated with
reduced PGN cross-linking might be a result of larger EVs that
would carry an increased cargo load, we quantiﬁed EVs by
nanoparticle tracking analysis. As shown in Fig. 3i, treatment of
JE2 cultures with PenG or mutation of pbp4 or tagO resulted in
suspensions containing signiﬁcantly greater numbers of EV
Fig. 3 Reductions in peptidoglycan cross-linking increase S. aureus EV production and size. a Dot blots were performed on JE2 EVs treated with
subinhibitory concentrations of penicillin G (PenG) or erythromycin (Em) and probed with mouse EV antiserum. b EV protein abundance was quantiﬁed
and expressed as ng EV protein ml−1 culture. c EV production from S. aureus strains JE2, MW2, COL, or their isogenic penicillin-binding protein 4 (pbp4)
mutants was evaluated by dot-blotting EV suspensions or d by quantiﬁcation of total EV protein yield. e EV production from strains JE2, COL, Newman, and
their ΔtagO (WTA-deﬁcient) or ΔdltA (lacking alanine modiﬁcations on WTA) mutants was evaluated by dot-blotting EV suspensions or f by
quantiﬁcation of total protein yield. g The size distribution and h average size of EVs isolated from JE2, PenG treated JE2, and Δpbp4 and ΔtagO mutants
were measured by dynamic light scattering. i EV particles from JE2, PenG treated JE2, and Δpbp4 and ΔtagO mutants were quantiﬁed by nanoparticle
tracking analysis. Electron micrographs of j JE2 cells treated with PenG or k carrying a pbp4 mutation are shown. Scale bar, 200 nm. Dot immunoblot
assays were performed at least twice with similar results; a representative blot is shown. EV protein yield and EV particle quantiﬁcation experiments were
calculated from at least three independent experiments and expressed as mean ± s.e.m. The data were analyzed using one-way ANOVA with Dunnett’s
multiple comparison test (Fig. 3b, h, i) or using Student’s t-test (Fig. 3d, f). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001
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particles per ml compared to untreated WT EVs. Electron
micrographs of bacterial cells treated with PenG (Fig. 3j) or
carrying a pbp4 mutation (Fig. 3k) showed EVs being released or
budding, respectively, from the cell membrane. Taken together,
our data indicate that S. aureus EV production is inversely
proportional to the degree of PGN cross-linking.
Autolysin Sle1 promotes the release of EVs. Atl and Sle1 belong
to a family of PGN hydrolases that plays a critical role in
separation of daughter cells30,31, and Atl modulates the excretion
of a subset of staphylococcal cytoplasmic proteins4. To determine
whether PGN-hydrolases facilitate the release of EVs by altering
the thick Gram-positive cell wall, we compared EV production
from isogenic atl and sle1 mutants with that of strains JE2 and
Newman. Although both mutants showed reduced EV produc-
tion (Fig. 4a), the reduction in yield was only signiﬁcant in the
sle1 mutants (Fig. 4b). Likewise, NTA revealed that only the sle1
mutant yielded a signiﬁcantly lower EV concentration compared
to WT JE2 (Fig. 4c). Complemention with pSle1 expressing the
sle1 gene, but not the pOS1-hprK vector alone, fully restored EV
production to the JE2 Δsle1 mutant (Fig. 4b, c). Both atl and sle1
mutants exhibited signiﬁcantly reduced EV size compared to WT
JE2 EVs (Fig. 4d, e).
Bacteriophages also produce PGN hydrolases called endolysins,
which degrade the bacterial cell wall from within, resulting in cell
lysis and release of progeny phages. Recently, Toyofuku et al.14
reported that prophage-encoded endolysins mediate the forma-
tion and release of EVs from Bacillus subtilis by generating a hole
in the cell wall, leading to cell death. To investigate whether
prophages or prophage-encoded endolysins are involved in S.
aureus EV production, we analyzed S. aureus strains NCTC 8325
carrying ϕ11, ϕ12, and ϕ13 and 8325-4, which is cured of all three
prophages32. Plating culture ﬁltrates of NCTC 8325 on lawns of
recipient strain RN4220 resulted in the formation of plaques,
whereas culture ﬁltrates of 8325-4 yielded no plaques
(Supplementary Fig. 2a). EV yields and NTA revealed that
NCTC 8325 and prophage-free strain 8325-4 produced compar-
able level of EVs (Supplementary Fig. 2b and 2c), indicating that
prophage mobilization is not essential for the generation of S.
aureus EVs.
Effects of the S. aureus capsule on EV release. To determine
whether the presence of capsular polysaccharide (CP) production
impacted S. aureus EV biogenesis, we evaluated a number of
isogenic CP+ and CP− strains. As shown in Fig. 5a, the CP
phenotype had no obvious impact on the EV dot blot signal
derived from WT or CP− mutants of strains Newman (CP5+) or
6850 (CP8+). Similarly, USA300 strain 923 (complemented to
restore CP5 production) produced CP533, but there was no effect
on the EV signal levels achieved by dot blotting (Fig. 5a). Like-
wise, CP+ and isogenic CP− strains of Newman, 6850, and 923
produced comparable protein yields of EVs (Fig. 5b), indicating
that CP did not modulate S. aureus EV production.
To investigate whether CP antigens were associated with S.
aureus EVs, we performed CP immunoblots on EVs prepared
from strains Newman (CP5+), MN8 (CP8+), and USA300
FPR3757 (CP−). CP antibodies react with surface-associated CP
on intact EVs, whereas intravesicular CP would only be detected
in sonicated EV preparations. Figure 5c shows that CP5 was only
detected in sonicated, but not intact Newman EVs; whereas, CP8
was detected in both intact and sonicated MN8 EVs. EVs from
CP− FPR3757 were non-reactive. Thus, both CP5 and CP8 were
associated with EVs produced by CP+ S. aureus, although only
CP8 was surface exposed.
Detoxiﬁed EVs as a multicomponent vaccine platform. Multi-
ple antigens were packaged within JE2 EVs, including lipopro-
teins, cytolytic toxins, surface proteins, and enzymes
(Supplementary Data 1). If the toxicity of the EVs were
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Fig. 4 The autolysin Sle1 promotes EV biogenesis. a EV production from JE2 and different autolysis mutants (Δatl and Δsle1) was evaluated by dot-blotting
EV suspensions, b by quantiﬁcation of total EV protein abundance, or c by EV quantiﬁcation using nanoparticle tracking analysis. d The size distribution and
e average size of EVs isolated from JE2 and the Δatl and Δsle1 mutants were measured by dynamic light scattering. The dot immunoblot assay was
repeated at least twice with similar results; a representative blot is shown. EV protein yield and EV particle quantiﬁcation experiments were calculated from
at least three independent experiments and expressed as mean ± s.e.m. The data were analyzed using one-way ANOVA with Dunnett’s multiple
comparison test (Fig. 4b, c, e), For all panels, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001
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eliminated, JE2 EVs could serve as a multicomponent S. aureus
vaccine candidate. To repress the expression of cytolytic toxins,
we mutated the S. aureus global regulator agr in strain JE2. We
subsequently deleted spa (the gene encoding protein A) since an
agr mutant overexpresses Spa, which binds to the Fcγ domain of
immunoglobulin and dampens antibody development by cross-
linking the Fab domain of VH3-type B-cell receptors34. The JE2
agr mutation signiﬁcantly inhibited mRNA expression of hla
(encoding alpha toxin) and the genes encoding all nine leukocidin
subunits (Supplementary Fig. 3a). The JE2ΔagrΔspa double
mutant served as our S. aureus EV vaccine producing host strain.
EVs from JE2, but not the JE2ΔagrΔspa mutant, contained native
Hla and LukE (Supplementary Fig. 3b) as assessed by western
blotting. When we analyzed the protein content of JE2ΔagrΔspa
EVs by LC–MS/MS, many of the extracellular proteins present in
JE2 WT EVs were not detected in JE2ΔagrΔspa EVs. However,
some antigens such as MntC and FhuD2 that protect mice against
experimental S. aureus infections35,36 were present in EVs from
the mutant strain. Neither protein A nor the toxins Hla, Panton-
Valentine leukocidin (Luk-PVL), LukED, HlgCB, SelX, or PSMs
were detectable in EVs puriﬁed from the JE2ΔagrΔspa mutant
(Supplementary Data 2). Although LukAB was still present in
EVs from JE2ΔagrΔspa, there was ≥86% reduction in the number
of peptides detected in the mutant strain (Supplementary Data 1
and 2). Moreover, as indicated below, EVs recovered from the
mutant strain showed no residual toxicity toward human
leukocytes.
We immunized mice with 5 µg EVs from JE2Δagr or
JE2ΔagrΔspa mutants; control mice were given phosphate
buffered saline (PBS). EVs from both mutants elicited a serum
antibody response against sonicated WT EVs, although the
antibody level elicited by Δagr EVs was higher than that elicited
by ΔagrΔspa EVs (Supplementary Fig. 4a). To examine the
antigen proﬁles from EVs that elicited antibody responses after
immunization, a bacterial lysate from USA300 strain FPR3757
was subjected to SDS-PAGE and immunoblotted with sera pooled
from mice immunized with either Δagr EVs or ΔagrΔspa EVs.
Sera from ΔagrΔspa EVs-immunized mice reacted with more
bacterial antigens than sera from Δagr EVs-immunized mice
(Supplementary Fig. 4b), suggesting that ΔagrΔspa EVs elicited a
greater diversity of antibodies than Δagr EVs. The immunized
mice were then challenged with strain FPR3757, a heterologous
USA300 isolate. Immunization of mice with EVs from JE2ΔagrΔ-
spa, but not EVs from JE2Δagr, provided signiﬁcant protection
against lethal sepsis (Supplementary Fig. 4c). Immunization with
higher doses of JE2ΔagrΔspa EVs mixed with alum did not
signiﬁcantly enhance immunogenicity (Supplementary Fig. 4d).
Engineered EVs protect mice against lethal sepsis. To enhance
the protective efﬁcacy of detoxiﬁed EVs from JE2ΔagrΔspa, we
engineered JE2 to package non-toxic HlaH35L37 and the LukE
monomer within eng-EVs. LukED, detected in 82% of blood
isolates and 61% of nasal isolates38, targets human and murine
neutrophils, macrophages, T cells, dendritic cells, NK cells, and
erythrocytes39.
We expressed non-toxic HlaH35L and LukE in strain JE2ΔagrΔ-
spa under control of the spa promoter, which is enhanced in an
Δagr genetic background40. Thus, mRNA levels of HlaH35L and
LukE expressed in JE2ΔagrΔspa were dramatically increased
compared to expression in JE2ΔagrΔspa or JE2ΔagrΔspa with the
empty vector (Supplementary Fig. 3c). Both HlaH35L and LukE
were detected by western blot in eng-EVs isolated from
recombinant strain JE2ΔagrΔspa (pHlaH35L-LukE) (Supplemen-
tary Fig. 3b).
The relative toxicity of EVs prepared from WT strain JE2 and
JE2ΔagrΔspa vs. eng-EVs from JE2ΔagrΔspa (pHlaH35L-LukE)
was assessed by incubating EVs in vitro with three different cell
types. A549 cells are susceptible to Hla-mediated cytolysis, and
WT strain JE2 EVs were toxic for A549 cells at concentrations as
low as 1 µg ml−1. In contrast, JE2ΔagrΔspa mutant EVs and the
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Fig. 5 Effects of S. aureus capsular polysaccharide synthesis on EV
production. a EV production from encapsulated S. aureus (Newman, 6850,
923 [pCP5]) or their CP-negative counterparts (NewmanΔcap5O,
6850ΔcapHIJK, and 923) was evaluated by dot-blotting EV suspensions or
b by quantiﬁcation of total EV protein yield. c CP5 or CP8 was detected in
intact or sonicated EVs (35 µg) from strains Newman, MN8, or FPR3757 by
immunoblots probed with 1.2 µg ml−1 CP5-speciﬁc mAb 4C2 or CP8-
speciﬁc mAb 5A6. Controls included 15 µg puriﬁed CP5 and CP8. The dot
immunoblot assay was repeated at least twice with similar results; a
representative blot is shown. EV protein yields were calculated from at least
three independent experiments and expressed as mean ± s.e.m.
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eng-EVs from JE2ΔagrΔspa (pHlaH35L-LukE) exhibited negligible
toxicity (Supplementary Fig. 5a). HL60 cells are susceptible to the
cytolysis induced by S. aureus leukocidins, and JE2 EVs, but not
ΔagrΔspa or eng-EVs, were cytolytic for HL60 cells (Supplemen-
tary Fig. 5b). Rabbit erythrocytes are susceptible to Hla, PSMs,
and the leukocidins HlgAB and LukED39. JE2 EVs exhibited
signiﬁcant hemolytic activity, whereas no hemolysis resulted from
ΔagrΔspa mutant EVs or eng-EVs (Supplementary Fig. 5c). These
data demonstrate that the eng-EVs were non-toxic in vitro for
mammalian cells.
We immunized mice on days 0, 14, and 28 with 5 µg eng-EVs
from JE2ΔagrΔspa (pHlaH35L-LukE) or with 5 µg EVs from the
JE2ΔagrΔspa mutant; control mice received 5 µg bovine serum
albumin (BSA). Whereas sera from mice immunized with both
eng-EVs and ΔagrΔspa EVs, but not BSA, reacted by ELISA with
sonicated WT JE2 EVs (Fig. 6a), only mice given the eng-EVs
responded with antibodies to puriﬁed Hla (Fig. 6b) or LukE
(Fig. 6c). These data indicate that recombinant proteins packaged
within S. aureus EV are immunogenic.
To examine whether the antibodies elicited by the eng-EV
vaccine were functional, toxin neutralizing assays were per-
formed. Sera from mice immunized with eng-EVs effectively
neutralized Hla at dilutions ranging from 1:20 to 1:80 (Fig. 6d),
whereas serum neutralizing antibodies were low or undetectable
in the BSA or ΔagrΔspa EV groups. Similarly, sera from mice
immunized with eng-EVs, but not BSA or ΔagrΔspa EVs, were
able to effectively neutralize LukED at dilutions ranging from 1:10
to 1:20 (Fig. 6e). Sera from mice immunized with eng-EVs also
neutralized leukocidin HlgAB (Fig. 6f), but not PVL-SF or HlgCB
leukotoxins.
The immunized mice were challenged with USA300 strain
LAC or USA500 strain NRS685, a PVL-negative MRSA
bacteremia isolate. We chose the latter strain because the PVL-
S and PVL-F subunits can interact with LukE and LukD to form
inactive hybrid complexes, which have been shown to inﬂuence
LukED-mediated S. aureus virulence in mice41. As shown in
Fig. 6g, h, immunization with eng-EVs provided signiﬁcant
protection against both S. aureus isolates in the lethal murine
sepsis model. JE2ΔagrΔspa EVs were not protective against the
USA500 strain (Fig. 6h).
Discussion
The production of membrane vesicles represents a secretory
pathway common to mammalian cells, fungi, and bacteria that
allows cell-free intercellular communication42–44. Microbial EVs
encapsulate cargo that include lipids, proteins, glycans, and
nucleic acids, which have been shown to play roles in
microbial physiology, pathogenesis, and the transmission of
biological signals into host cells to modulate biological
processes and host innate immune responses42,43,45,46. In
Gram-negative bacteria, EVs are generated by pinching off the
outer membrane, but the mechanism(s) by which EVs escape
the thick cell walls of Gram-positive bacteria, mycobacteria, and
fungi are unknown. Once shed, S. aureus EVs can undergo
cholesterol-dependent fusion with host cell membranes to deliver
their toxic cargo47. S. aureus EVs are produced in vivo during
experimental pneumonia in mice47. In this report, we
demonstrate unique properties associated with EV production by
JE2, a S. aureus USA300 strain representative of the prevalent
CA-MRSA clone in the US. Similar to EVs characterized
from other S. aureus isolates47–49, JE2 EVs encapsulate an array
of bacterial antigens, including lipoproteins, exotoxins, and
cytoplasmic proteins.
In this report, we evaluated putative factors that modulate the
membrane and PGN related steps of EV release. PSMs are a
group of small alpha helical peptides that have surfactant-like
properties and potent cytolytic activity for leukocytes, epithelial
cells, and endothelial cells20. PSMα peptides are 20–22 amino
acids in length; whereas, PSMβ peptides are 43–45 amino acids in
length. In our studies, PSMα peptides, but not PSMβ peptides,
supported the generation of EVs from S. aureus. EVs from the
PSMα mutant were less abundant and smaller in size compared
with WT EVs. Chatterjee et al.50 reported that an S. aureus
mutant that lacks the PSM transporter protein accumulates PSMs
intracellularly, causing cytoplasmic membrane perturbations.
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Fig. 6 Immunogenicity and protective efﬁcacy in mice of engineered-EVs. Antibody levels in sera (diluted 1:100) from mice immunized with eng-EVs were
analyzed on ELISA plates coated with a JE2 sonicated EVs, b Hla, or c LukE. Data were expressed as mean ± s.e.m. The neutralizing activity of sera from
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EV-immunized mice vs. BSA-immunized mice) was analyzed with the log-rank test
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Surfactants or surfactant-like proteins with amphipathic helical
structures have been shown to insert into lipid monolayers and
generate local deformation51,52. PSMs, due to their surfactant-like
activity, as well as amphipathic helical structure, may enhance
membrane curvature under cytoplasmic turgor pressure, resulting
in membrane disruption and the formation of EVs. Although EVs
from Gram-negative bacteria arise from the outer membrane
rather than the plasma membrane, the biogenesis of OMV pro-
duction is also thought to be due to perturbations in the outer
leaﬂet of the membrane due to speciﬁc phospholipid accumula-
tion therein11. Recently, Ebner et al.5 reported that S. aureus
PSMα peptides-induced the cellular release of cytoplasmic pro-
teins, lipids, nucleic acids, and ATP into culture supernatants,
and that this effect was mediated by the membrane-damaging
activity of the PSMα peptides. Because PSMα peptides promote
EV production, and EVs encapsulate cytoplasmic proteins, lipids,
and nucleic acids18 within a bilayered membrane, we postulate
that these released cellular components are associated with and
are likely contained within EVs.
The S. aureus cell envelope is comprised of a thick, highly
cross-linked PGN layer, proteins, and glycopolymers like lipo-
teichoic acid, WTA, and CP. Highly cross-linked PGN serves as a
barrier for EV biogenesis since treatment of S. aureus with a
sublethal concentration of PenG or genetic inactivation of pbp4 or
tagO resulted in a signiﬁcant increase in EV production and size.
This inverse correlation between PGN cross-linking and EV yield
was also observed with S. aureus strains MW2, COL, and New-
man. WTA has been shown to be critical for PGN-cross-linking
by regulating PBP4 localization to the septation site28. A sec-
ondary mechanism by which WTA regulates EV production is via
its ability to control the activity of Atl and Sle1—not only by
preventing their binding to S. aureus cell wall PGN53,54, but also
by creating an acidic milieu that limits Atl PGN hydrolase
activity55. Consequently, autolytic activity is not localized to the
septum area in a tagO mutant but is spread throughout the cell
surface, likely facilitating EV release. Schlag et al.53 reported that
a tagO mutant showed an altered cell surface with bobble- and
hairy-like protrusions, which may represent EVs. Although we do
not yet fully understand the mechanism(s) of EV generation in
Gram-positive bacteria, it seems logical that a poorly cross-linked
cell wall or a cell wall lacking WTA would lessen the barrier to EV
release and generate larger EVs as a result of larger pores within
the PGN structure.
Autolysins that cleave the PGN barrier also impact the bio-
genesis of S. aureus EVs. Atl and Sle1 localize to the septum
during cell division where they exhibit peptidoglycan hydrolase
activity, resulting in separation of the daughter cells53,54. Sle1 is a
32 kDa protein comprised of an N terminal cell wall binding
domain and a C terminal catalytic domain with N-acetyl mur-
amyl-L-alanine amidase activity. In contrast, Atl is a 138 kDa
bifunctional PGN hydrolase that is processed to yield a 62 kDa
protein with amidase activity (similar to that of Sle1) and a 51
kDa protein with endo-β-N-acetyl glucosaminidase activity. Atl is
also involved in cell wall turnover and penicillin- or detergent-
induced bacterial autolysis. Deletion of sle1, but not atl, sig-
niﬁcantly reduced S. aureus EV production. Pasztor et al.4
reported that an SA113 atl mutant overexpressed eight putative
secondary PGN hydrolases both at the transcriptional and at the
protein levels, highlighting the supplementary role of these
alternative autolysins in the absence of Atl. This observation may
at least partially explain why JE2Δatl and NewmanΔatl showed
only a modest reduction in EV yield. Mutation of atl only slightly
reduced EV yield, but the average size of EVs from the mutant
was smaller than that of WT JE2, suggesting that Atl is involved
in EV biogenesis. Atl modulates the excretion of staphylococcal
cytoplasmic proteins4, and it is likely that EV production at least
partially explains the Atl-mediated shedding of cytoplasmic
proteins in S. aureus.
Although both autolysin activities are localized to the S. aureus
septum region, JE2 EVs are not conﬁned to the septal region
(Fig. 2f), and EVs have been visualized by others surrounding the
bacterial surface7,48,56. A recent report demonstrated differential
roles for Atl and Sle1 during cell division and separation57.
Whereas Sle1 could be visualized over the entire septal surface,
Atl localized only at the external (surface exposed) edge of the
septum58. How autolysins modulate EV release from the cell wall
or whether this process is spatially or temporally regulated
remains to be determined.
We reported that S. aureus CP was shed from broth-grown S.
aureus cells59, and it is feasible that EVs could serve as a vehicle to
liberate CP from the cell envelope. The Streptococcus pneumoniae
capsule was reported to hinder EV release in this pathogen7,
whereas no effect was observed on EV yield in strains with or
without the hyaluronic capsule of Streptococcus pyogenes8.
Whether these streptococcal CPs are present as EV cargo in these
pathogens was not addressed. Although EV yield varied among
different isolates, we recovered similar quantities of EVs from
isogenic S. aureus strains that varied only in CP production. The
glucuronoxylomannan capsule of Cryptococcus neoformans has
been identiﬁed as a component of EVs from this fungal patho-
gen60, and polysaccharide A from Bacteroides fragilis was shown
to be packaged into OMVs that were capable of inducing
immunomodulatory signaling in dendritic cells46. Ongoing stu-
dies in our laboratory will address whether S. aureus EV-host cell
interactions impact the pathogenesis of staphylococcal disease.
We considered that S. aureus EVs could serve as a vaccine
platform if their cytotoxicity was abrogated, and this was
accomplished by purifying EVs from an ΔagrΔspa mutant of
strain JE2. To enhance the protective efﬁcacy of the ΔagrΔspa EV
vaccine, non-toxic HlaH35L and LukE were expressed in
JE2ΔagrΔspa under the control of the agr-derepressed spa pro-
moter. Immunization with puriﬁed non-toxic HlaH35L has been
shown to prevent lethal pneumonia and lethal peritonitis and
reduce the incidence of necrotic skin abscesses61–63. S. aureus
leukocidins comprise a family of pore-forming cytolysins pro-
duced by S. aureus that target monocytes, lymphocytes, neu-
trophils, and macrophages—the very cells responsible for
resolution of bacterial infection. These “eng-EVs” elicited anti-
bodies in the sera of immunized mice that reacted with Hla and
LukE by ELISA and neutralized the cytolytic activity of Hla,
LukED, and HlgAB in vitro.
Immunization with eng-EVs provided signiﬁcant protection
against lethal sepsis provoked by USA300 strain LAC, a virulent
PVL+ isolate. Because of a report that the presence of PVL
modulates LukED-mediated S. aureus virulence in mice41, we
challenged another group of immunized mice with USA500 strain
NRS685, a PVL-negative MRSA bacteremia isolate. Immuniza-
tion with eng-EVs, but not ΔagrΔspa EVs, protected 50% of the
mice against NRS685 lethal sepsis. Protective efﬁcacy against
additional S. aureus strains and in additional infection models
remains to be evaluated. Overexpression of additional antigens
that have been shown to protect mice against experimental S.
aureus infections, such as MntC and FhuD235,36, in second-
generation eng-EVs may yield a more broadly protective vaccine.
LC–MS/MS analysis of EVs from both WT JE2 and the ΔagrΔspa
mutant strain contained multiple lipoproteins. As a predominant
TLR2 ligand, lipoproteins have been increasingly used as adjuvant
components64,65 because they are potent activators of host innate
immunity and can mediate humoral and cell mediated immune
responses. The self-adjuvanting composition of eng-EVs may
provide it with a unique advantage over puriﬁed component
vaccines.
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In summary, we have generated, puriﬁed, and characterized
EVs isolated from S. aureus USA300, the predominant CA-MRSA
clone in the United States. Our study revealed that S. aureus
PSMs are central for EVs generation by targeting the cytoplasmic
membrane. Likewise, the Sle1 autolysin was shown to be critical
for the release of EVs from the S. aureus cell wall. Whereas
mutations in Atl or CP production did not affect EV yield, PBP4
and WTA promoted PGN cross-linking and consequently
diminished EV production. Our study elucidates certain
mechanisms whereby S. aureus produces and sheds EVs (Fig. 7)
and will ultimately further our understanding of bacterial phy-
siology and pathogenesis. We designed and created eng-EVs as a
vaccine platform against S. aureus infection. Detoxiﬁed EVs that
over-produced HlaH35L and LukE were immunogenic, elicited
toxin neutralizing antibodies, and protected mice in a S. aureus
lethal sepsis model, indicating that these naturally produced
vesicles have potential as a noval vaccine platform.
Methods
Bacterial strains and plasmids. S. aureus isolates (listed in Supplementary
Table 1) were cultivated overnight with aeration in tryptic soy broth (TSB; Difco) at
37 °C. Escherichia coli strain XL-10 (Agilent), used in DNA cloning experiments,
was grown at 37 °C in Luria Broth (LB; Difco). S. aureus—E. coli shuttle vector
pCU166 was used for cloning and expression of appropriate genes in S. aureus, and
pOS1-hprK was used for pSle1 complementation studies. Antibiotics were added in
the following concentrations: PenG 0.2 μg ml−1, ampicillin (Amp; 100 μg ml−1),
Em 5 μg ml−1, chloramphenicol (Cm; 10 μg ml−1), kanamycin (Kan; 50 μg ml−1),
and tetracycline (Tet; 5 μg ml−1).
DNA manipulation. Fey et al.19 derived S. aureus JE2 from the USA300 strain LAC
by curing it of plasmids, rendering it sensitive to Em. The agr mutation (Δagr::
tetM) was transduced from S. aureus RN691140 to WT JE2 using bacteriophage
ϕ80α with selection for Tet resistance. To construct the JE2 ΔagrΔspa double
mutant, the spa mutation was transduced from JE2 (spa::ermB) to JE2Δagr by ϕ80α
transduction. The pbp4 mutation was transduced from JE2 (Δpbp4::ermB) to WT
MW2 and COL by ϕ80α transduction with selection for Em resistance. All mutants
were conﬁrmed by PCR using the primers listed in Supplementary Table 2. ELISA
results conﬁrmed the phenotype of the Δspa mutant, and the agr mutant lost its
hemolytic phenotype. To construct the WTA mutants, the tagO mutation was
transduced from SA113ΔtagO (pRBtagO) to WT JE2 and COL with ϕ80α with
selection for Em resistance. Mutants were conﬁrmed by PCR and acquisition of
resistance to lysis by ϕ80α. To complement the JE2Δsle1 mutant, a DNA fragment
of 1005 bp containing the sle1 gene was ampliﬁed from JE2 genomic DNA using
the primer pair listed in Supplementary Table 2. The Sle1 expression plasmid was
constructed by cloning the sle1 gene under the control of the hprK promoter into
the E.coli—S. aureus shuttle vector pOS167. pSle1 was transformed into RN4220 by
electroporation and then transduced to JE2Δsle1 by ϕ80α transduction.
To construct a shuttle vector for expression of HlaH35L and LukE, the spa
promoter, hlaH35L, and lukE genes were ampliﬁed from S. aureus strains JE2,
DU1090 (pHlaH35L), and FPR3757, respectively, using the primers listed in
Supplementary Table 2. To drive the expression of hlaH35L, its sequence was fused
to the 3′ terminus of the spa promoter containing the ribosome binding site by
overlapping PCR. The Pspa-hlaH35L fusion sequence was cloned into the shuttle
plasmid pCU1 with restriction enzymes HindIII and SalI. The ampliﬁed lukE
sequence containing a ribosome binding site was inserted into pCU1 with
restriction enzymes SalI and EcoRI. The resulting plasmid pCU1-Pspa-hlaH35L-lukE
was veriﬁed by enzyme digestion and DNA sequencing. To construct JE2ΔspaΔagr
expressing non-toxic HlaH35L and LukE, pCU1-Pspa-hlaH35L-lukE was transformed
into RN4220 by electroporation and then transduced with ϕ80α to JE2ΔspaΔagr,
selecting for Cm resistance.
Isolation and puriﬁcation of EVs. S. aureus was cultivated in TSB with shaking to
an OD650 nm of 1.2. The culture supernatant was ﬁltered and concentrated 25-fold
with a 100-kDa tangential ﬂow ﬁltration system (Pall Corp.). The retentate was
ﬁltered again before centrifugation at 150,000×g for 3 h at 4 °C to pellet the vesicles
and leave soluble proteins in the supernatant. The EV pellet was suspended in 40%
Optiprep density gradient medium (Sigma) and overlaid with gradient layers of
Optiprep ranging from 35 to 10%. After centrifugation at 139,000×g for 16 h at
4 °C, 1 ml fractions were removed sequentially from the top of the gradient. Each
fraction was subjected to SDS-PAGE and stained with a Thermo Fisher silver
staining kit. Fractions with a similar protein proﬁle on SDS-PAGE were pooled,
Cytoplasmic membrane
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PSMα peptides
Cell wall
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Detoxified
Wall teichoic acid
Lipoprotein EV
Fig. 7 Proposed mechanisms underlying EV production by Staphylococcus aureus. EVs are generated from the cytoplasmic membrane, and this process is
promoted by S. aureus PSMα peptides, which have surfactant-like activity, causing membrane disruption. Membrane-derived EVs must also traverse the
highly cross-linked S. aureus peptidoglycan barrier, and the extent of cell wall cross-linking modulates the efﬁciency of EV production. Autolysins, such as
Sle1, facilitate EV release by hydrolyzing peptidoglycan, particularly at sites of active cell division. We mutated S. aureus to render its EVs non-toxic, and
then genetically engineered the mutants to package detoxiﬁed antigens in EVs. These recombinant EVs were immunogenic in mice and showed protective
efﬁcacy in a sepsis model of S. aureus infection
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and the Optiprep medium was removed by diaﬁltration with PBS using an Amicon
Ultra-50 Centrifugal Filter Unit. The diaﬁltered retentate was ﬁltered (0.45 µm) and
stored at 4 °C. EV protein concentrations were determined by using a Protein
Assay Dye Reagent (Bio-Rad). EV samples were evaluated with a Nanobrook
ZetaPALS potential analyzer (Brookhaven Instruments Corp.), and the data for size
distribution and particle diameter were generated with ZetaPALS particle sizing
software. Nanoparticle tracking analysis was performed by purifying EVs from 100
ml bacterial cultures, as described above. The number of EV particles recovered
from individual cultures (and suspended in 1 ml PBS) was determined using a
Nanosight NS300 Sub Micron Particle Imaging System (Malvern). A camera level
of 12 and a gain of 1 was utilized to optimize data collection, and analyses were
performed with Nanoparticle Tracking and Analysis software (NTA 3.1). Each
sample was analyzed three times for 30 s at 20 °C using different ﬁelds of view.
Frame sequences were analyzed under manual particle detection and tracking
parameters (screen gain of 4 and detection threshold of 17).
Transmission electron microscopy. For imaging S. aureus ultrathin sections, the
cultures were ﬁxed with 2.5% paraformaldehyde, 5% glutaraldehyde, and 0.06%
picric acid in cacodylate buffer and postﬁxed with 1% osmium tetroxide/1.5%
potassium ferrocyanide. After incubation in 1% uranyl acetate, samples were
sequentially dehydrated in ethanol before they were soaked in propylene oxide and
inﬁltrated overnight with propylene oxide and TAAB Epon. Ultrathin sections
were stained with lead citrate. To image EVs, 5 µl S. aureus EVs were adsorbed for
1 min to a carbon coated grid that was made hydrophilic by a 30-s exposure to a
glow discharge. The samples were stained with 0.75% uranyl formate. All samples
were examined in a TecnaiG2 Spirit BioTWIN transmission electron microscope,
and images were recorded with an AMT 2k CCD camera.
Proteomic analysis of EVs by LC–MS/MS. S. aureus EVs (8–10 µg) were sub-
jected to SDS-PAGE and stained with Coomassie Blue R-250. Gel sections were
analyzed at the Taplin mass spectrometry facility at Harvard Medical School using
an LTQ Orbitrap Velos Pro ion-trap mass spectrometer (Thermo Fisher). Peptide
sequences (and hence protein identity) were determined by matching protein
databases with the acquired fragmentation pattern using the software program
Sequest (Thermo Fisher Scientiﬁc). Proteins were identiﬁed by a minimum of two
peptides and at least one unique peptide. Sequence analysis was performed with a
database containing protein sequences of the S. aureus USA300 FPR3757 genome
downloaded from NCBIprot. The subcellular localization of each identiﬁed protein
was predicted by PsortB v.3.0 (www.psort.org/psorb/).
Real-time RT-PCR assay. S. aureus strains were cultivated in 5 ml TSB at 37 °C to
an OD650 nm of 0.9. After centrifugation at 4 °C, the bacterial cells were mixed with
glass beads in 300 µl lysis buffer (RNeasy mini kit; Qiagen) and lysed by using a
high speed Ultramat 2 Amalgamator (SDI, Inc.). Total RNA from the lysate
supernatant was puriﬁed with the RNeasy mini kit (Qiagen), treated with DNase I
(Invitrogen), and stored at −70 °C. cDNA was synthesized from 1 µg of bacterial
RNA using a Protoscript II First Strand cDNA synthesis kit (New England Bio-
labs). A total of 50 ng of synthesized cDNA was subjected to Real-time RT-PCR
using a Power Green PCR Master Mix (Applied Biosystems) with primers listed in
Supplementary Table 2 and detected in a StepOnePlus Real-Time PCR System
(Applied Biosystems). The relative transcriptional levels of hlaH35L and lukE were
calculated using the ΔΔCt method by normalizing to the 16S rRNA transcriptional
level.
Immunoblotting assays. For western blots, 10 µg S. aureus EVs were subjected to
SDS-PAGE, transferred to nitrocellulose membranes, and blocked with PBS+
0.05% Tween-20 (PBST) and 1% skim milk for 1 h at room temperature (RT). After
washing with PBST, the membranes were incubated with rabbit anti-LukS-PV
(2 μg ml−1; IBT Bioservices; Cat. No. 04-0009) or mouse anti-Hla monoclonal
antibody (mAb) 6C12 (1 μg ml−1; IBT Bioservices; Cat. No. 0210-005) overnight at
4 °C. The membranes were washed and incubated with HRP-conjugated goat anti-
rabbit IgG (1:5000; ImmunoReagent, Inc.; Cat. No. GtxRb-004-DHRPX) or anti-
mouse IgG (1:5000; ImmunoReagent, Inc.; Cat. No. GtxMu-004-DHRPX) for 2 h at
RT before developing the blots using TMB membrane peroxidase substrate (Kir-
kegaard & Perry Laboratories, Inc). Puriﬁed Hla (List Biological Labs) and LukE
(IBT Bioservices) were used as positive controls. Uncropped scans of the western
blots are shown in Supplementary Fig. 6.
For EV dot blotting assays, intact or sonicated EVs were applied to
nitrocellulose membranes using a 96-well dot blotter system (Bio-Rad). The
membranes were immersed in PBST + 5% skim milk for 2 h before blocking the
staphylococcal IgG binding proteins (Spa and Sbi) by overnight incubation at 4 °C
with an irrelevant human IgG1 monoclonal antibody (10 µg ml−1) in PBST+ 1%
skim milk. The membrane was washed with PBST and incubated overnight at 4 °C
with sera (diluted 1:1000 in PBST+ 1% skim milk) pooled from mice immunized
with EVs (see below) or murine mAbs59 to CP5 (4C2; 1.2 µgml−1) or CP8 (5A6; 1.2
µgml−1). After washes with PBST, the membrane was incubated with alkaline
phosphatase (AP)-conjugated goat anti-mouse antibody (1:15,000; Sigma; Cat. No.
A2429) at RT for 2 h. The membrane was washed with PBST and developed with AP
membrane substrate (KPL).
EV cytotoxicity. The relative toxicity of S. aureus EVs (1–20 µg ml−1) toward
human A549 lung epithelial cells (ATCC), neutrophil-like HL60 cells (ATCC), and
rabbit erythrocytes (Hardy Diagnostics) was assessed. A549 lung epithelial cells
grown in a 96-well plate were incubated overnight at 37 °C with EVs or 1 µg ml−1
of puriﬁed Hla. Toxicity was assessed using an LDH cytotoxicity assay kit (Thermo
Fisher Scientiﬁc). Differentiated HL60 cells (2 × 105 cells) were seeded in a 96-well
plate and treated with EVs or 1 µg ml−1 of PVL for 4 h at 37 °C. Cell viability was
measured with a CellTiter kit (Promega). A 2% rabbit erythrocyte suspension was
mixed with EVs or 1 µg ml−1 Hla in a 96-well plate for 1 h at 37 °C. The ery-
throcytes were pelleted by centrifugation, and hemolysis was recorded by mea-
suring the OD545 nm of the supernatant using an ELISA reader.
Animal studies. Mouse experiments were carried out in accordance with the
recommendations in the PHS Policy on Humane Care and Use of Laboratory
Animals, and animal use protocols were approved by the Partners Healthcare
Institutional Animal Care and Use Committee. Female Swiss Webster mice
(4 weeks old; Charles River) were immunized by the subcutaneous route on days 0,
14, and 28 with 5 µg of Δagr EVs, ΔagrΔspa EVs, or eng-EVs. Control animals were
immunized similarly with BSA (Sigma). Blood was collected from the mice by tail
vein puncture before each vaccination and again before challenge. Sera were diluted
1:100 and tested by ELISA on 96-well plates coated with 5 µg ml−1 sonicated WT
EVs, 5 µg ml−1 LukE, or 1 µg ml−1 Hla. Immunized mice were inoculated with
0.8–2 × 108 CFU S. aureus by intravenous (IV) tail vein injection 2 weeks after the
third vaccination. Survival was monitored up to 15 days post challenge, and the
data were analyzed using the log-rank test.
Toxin neutralization assays. For the Hla neutralization assays, mouse serum
samples were pre-incubated with native Hla for 1 h before the addition of 2% rabbit
erythrocytes. After 1 h, the cytotoxicity of the serum-neutralized samples was
measured by recording the OD545 nm of the sample supernatants68. For leukocidin
neutralization assays, blood was collected from healthy volunteers giving written
informed consent, as approved by the Institutional Review Board of The Brigham
and Women’s Hospital (Human Subject Assurance Number 00000484). Neu-
trophils were isolated from 10 ml blood using Polymorphprep (Accurate Chemi-
cal), washed, and suspended in RPMI (Invitrogen) containing 5% fetal bovine
serum (Invitrogen). Sera from immunized mice were serially diluted and mixed
with toxin concentrations yielding ~75% cell lysis (12.5 µgml−1 LukED, 2.5 µgml−1
PVL, 1 µgml−1 HlgAB, or 2 µgml−1 HlgCB (1∶1 S and F subunits). Samples were
pre-incubated with leukocidins for 30min at RT before the addition of neutrophils
(1.2 × 105 cells). After 2 h at 37 °C in 5% CO2, the cells were collected by cen-
trifugation and suspended in fresh medium. Cell cytotoxicity was evaluated using a
CellTiter kit (Promega). Percent neutralization was calculated using the formula: [%
cytotoxicity of (toxin+ cells)—% cytotoxicity of (serum+ toxin+ cells)].
Data availability. Data supporting the ﬁndings of this manuscript are
available from the corresponding author upon reasonable request. Mass spectro-
metry proteomics data were deposited in the ProteomeXchange Consortium
(http://proteomecentral.proteomexchange.org) via the PRIDE partner repository
with the data set identiﬁer PXD007953.
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